Genome Biologics products

GENIMAPS® and GENISYST® technology integration facilitates Ai-driven target identification, and direct therapeutic interrogation of RNAi disease targets in vitro (2D and 3D), and in small and large animal models. This coupled workflow enables efficient and accelerated RNAi target discovery and efficacy validation.